Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
15 participants
INTERVENTIONAL
2017-01-31
2018-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Reconsolidation Therapy With Propranolol as a Treatment for Chronic Pain
NCT05085782
Nondrug Treatment Programs for Adults With Fibromyalgia
NCT00088777
Efficacy Study of Relaxation to 12 Weeks Against Placebo in the Overall Care Chronic Pain in Patients With Fibromyalgia
NCT01628822
Endogenous Opioid Systems and Symptom Change in Fibromyalgia
NCT02866461
Fibromyalgia Study In Adults
NCT00256893
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Propranolol is not indicated to treat pain. However, the previous studies showed that low dose propranolol can re-regulate the adrenergic dysfunction and reduce pain in people with chronic musculoskeletal pain. However, the investigators are not aiming to develop a new indication of the drug.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
propranolol 1
20 mg propranolol twice a day
Propranolol 1
Participants will take 20 mg propranolol twice a day for 2 weeks
propranolol 2
10 mg propranolol twice a day
Propranolol 2
Participants will take 10 mg propranolol twice a day for 2 weeks
Placebo
Placebo twice a day
Placebo
Participants will take placebo twice a day for 2 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Propranolol 1
Participants will take 20 mg propranolol twice a day for 2 weeks
Propranolol 2
Participants will take 10 mg propranolol twice a day for 2 weeks
Placebo
Participants will take placebo twice a day for 2 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Uncontrolled/unstable illnesses (physician diagnosed, self-report)
* Pregnancy or planning to be pregnant in the next year
* Having Asthma requiring medication treatment including inhaler
* Type I diabetes or Type II diabetes requiring medical therapy that can lead to hypoglycemia
* Having acute pain or neuropathic pain
* Participation in exercise or psychological treatment studies in the past 2 years
* Having known serious psychopathology: Psychosis, history of inpatient psychiatric admission in the past year, active suicidal intent, history of self-injurious behaviors in the past year, history of recreational IV drug use, substance abuse history in the past year)
* Cardiovascular Criteria:
* Having known cardiovascular diseases (self-report, physician diagnosed)
* Pacemaker
* Bradycardia (resting heartrate of less than 55 bpm)
* Resting diastolic BP \< 55 mmHG or systolic BP\<100 mmHG
* ECG showing prolonged PR interval \> .2 sec
* ECG showing irregular PR interval
* ECG showing incongruence between P wave and QRS
* Medication Criteria
* Allergy or intolerance of beta blockers
* Current use of the following drugs:
* Antihypertensive drugs
* Neuroleptics
* Monoamine oxidase inhibitors
* Tizanidine
* Amphetamine-based medications
* Bupropion
* Mirtazapine
* Tricyclics: daily dose greater than 75mg amitriptyline or equivalent
* Benzodiazepine: daily dose greater than 5mg diazepam or equivalent
* Asthmatic medicine, including inhaler
* Participants may be included after minimum of 4 weeks of physician prescribed termination of these drugs
18 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Utah
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Akiko Okifuji
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Akiko Okifuji, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Utah
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Utah
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
00084875
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.